<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176277</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-7475-01</org_study_id>
    <nct_id>NCT03176277</nct_id>
  </id_info>
  <brief_title>A Study of ONO-7475 in Patients With Acute Leukemias</brief_title>
  <official_title>A Phase I Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and maximum tolerated dose of ONO-7475 in patients with
      relapsed or refractory acute leukemia and evaluate the efficacy of ONO-7475 in patients with
      newly diagnosed AML
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">November 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of (serious) Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in electroretinogram (ERG)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant ophthalmology examinations</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant electrocardiogram (ECG)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7475</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by the incidence, nature, and severity of (serious) Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of recommended pharmacological dose</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>As assessed by the Plasma inhibitory activity (PIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the plasma area under the curve (day 1 and 28) of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2)</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1</time_frame>
    <description>Assessment of the plasma decay half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough)</measure>
    <time_frame>Cycle 1 predose Day 7 and Day 15</time_frame>
    <description>Assessment of the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the maximum plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax) - - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the time to reach maximum observed plasma concentration of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the plasma area under the curve of ONO-7475</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the plasma decay half life of ONO-7475.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) - Food effect</measure>
    <time_frame>Day 57 (Cycle 3 Day 1)</time_frame>
    <description>Assessment of the food effect on the trough concentration of ONO-7475 in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of ONO-7475</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessment of the pharmacodynamic activity of ONO-7475 as assessed by a PIA assay (pAxl/pMer inhibition).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CR + CRi + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from PR, CRi and CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration in months from first study treatment to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time of disease relapse or patient death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time of treatment failure, disease relapse or patient death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Disease relapse (measured at CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by flow cytometry for patients who achieve CR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>ONO-7475: dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Successive dose escalation cohorts to determine MTD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7475</intervention_name>
    <description>ONO-7475 tablets</description>
    <arm_group_label>ONO-7475: dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged â‰¥18 years at time of screening

          2. Written informed consent by the patient (or legal representative) prior to admission
             to this study. In addition any locally required authorization (Health Insurance
             Portability and Accountability Act in the USA [HIPAA], obtained from the patient prior
             to performing any protocol-related procedures, including screening evaluations.

          3. Adequate renal and hepatic function defined as:

               -  Total bilirubin within 1.5 x ULN, except those with Gilberts syndrome for whom
                  this must be &lt;3 x ULN

               -  AST(SGOT) and ALT(SGPT) &lt;2.5 x ULN

               -  Calculated Creatinine clearance&gt;/= 45ml/min

               -  Serum Albumin &gt;3g/dL

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          5. Life expectancy of at least 3 months

          6. Sexually active female patients of childbearing potential and sexually active male
             patients must agree to use an effective method of birth control (e.g., barrier methods
             with spermicides, oral or parenteral contraceptives and/or intrauterine devices)
             during the entire duration of the study and for 4 months after final administration of
             study drug. Note that sterility in female patients must be confirmed in the patients'
             medical records and be defined as any of the following: surgical hysterectomy with
             bilateral oophorectomy, bilateral tubular ligation, natural menopause with last menses
             &gt;1 year ago; radiation induced oophorectomy with last menses &gt;1 year ago; chemotherapy
             induced menopause with last menses &gt;1 year ago.

          7. Male patients must use a condom from the time of the first administration of ONO-7475
             until 4 months following administration of the last dose.

        8. Diagnosis of AML according to WHO criteria 2016.

        9. Relapsed or refractory AML patients with at least 5% blasts by bone marrow biopsy or
        aspirate, or at least 1% blasts in peripheral blood, not likely to benefit from standard
        salvage chemotherapy.

        10. All patients must have received at least one prior therapy - 1 cycle of cytarabine
        containing regimen or 2 cycles of hypomethylating agent - before determination of
        refractory status (defined as response duration less than 3 months or no response)

        Exclusion Criteria:

          1. Primary disease involving the Central Nervous System (CNS)

          2. QTcF prolongation defined as a QTcF interval &gt;470 msec or other significant ECG
             abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia
             (ventricular rate &lt;50 beats/min).

          3. Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          4. HIV/active Hepatitis B infection

          5. Clinically significant (as defined by screening ophthalmologist) ERG reading, retinal
             disease (e.g. retinitis pigmentosa including Mertk mutations), retinal hemorrhage or
             any disorder which affects ERG, and may inhibit follow up for retinal toxicity

          6. Serious intercurrent medical or psychiatric illness that will prevent participation or
             compliance with study procedures, including serious active infection

          7. Acute promyelocytic leukemia (FAB M3 classification)

          8. Patients not recovered to Grade 1 or stabilized from the effects (excluding alopecia)
             of any prior therapy for their malignancies

          9. Concurrent treatment with other investigational drugs.

         10. Daily requirement for corticosteroids â‰¥ prednisone 10 mg/day or equivalent.

         11. Prior hematopoietic stem cell transplantation within 12 weeks of the first dose of
             study treatment or ongoing immunosuppressive therapy for graft versus host disease

         12. Participation in another clinical trial with any investigational drug within 30 days
             prior to study entry.

         13. Prior AML or ALL therapy (non-experimental) within 28 days of first dose of ONO-7475
             (except those permitted in the protocol)

         14. Prior radiotherapy within 21 days of screening. Localized radiation therapy to a
             single site within the last 7 days is acceptable. Concurrent radiotherapy is not
             permitted.

         15. Patients undergoing current treatments for other cancers

         16. Pregnant or lactating women

         17. Proliferative disease (WBC &gt; 30 x 109 /L) (confirmed at time of study entry prior to
             first dose)

         18. Diagnosed or treated for a malignancy other than AML within 5 years, or who were
             previously diagnosed with a malignancy other than AML and have any radiographic or
             biochemical marker evidence of malignancy. Note: Patients with completely resected
             basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy at
             any time are not excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ONO Pharma UK Ltd</last_name>
    <role>Study Director</role>
    <affiliation>Drug Development Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ONO Pharma UK Ltd</last_name>
    <phone>+44 (0)2074214920</phone>
    <email>ctinfo@ono-uk.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tara Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dale Bixby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eunice Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margaret Kasner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - Hollins Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brian Hess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myeloid, Acute</keyword>
  <keyword>MER</keyword>
  <keyword>MERTK</keyword>
  <keyword>TYRO3</keyword>
  <keyword>AXL</keyword>
  <keyword>AML</keyword>
  <keyword>de novo AML</keyword>
  <keyword>Relapsed/ Refractory AML</keyword>
  <keyword>TAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

